-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] In recent years, with the support of a series of favorable policies, China's innovative drug companies have gradually exerted their efforts, and their R&D investment has continued to increase.
The development of the entire innovative drug industry is in full swing
.
However, innovative drugs have the characteristics of high threshold, high investment and high risk
.
As the capital market continues to be optimistic about the innovative drug industry and continues to increase its weight in this field, it is expected to promote the further development of the industry
.
Junshi Bio announced on the evening of March 7 that it plans to raise no more than 3.
98 billion yuan for innovative drug research and development projects, Shanghai Junshi Biotechnology headquarters and research and development base projects
.
Among them, more than 90% of the funds raised this time will be used for innovative drug research and development projects
.
Regarding this fundraising, Junshi Bio said that after the investment project is completed, it will further promote the company's innovative drug research and development process, enrich the pipeline of drug products under development, enhance its research and development strength, and further enhance the company's core competitiveness
.
According to the data, Junshi Bio has a rich product pipeline and currently has a rich R&D pipeline consisting of more than 45 products under development, covering five therapeutic areas of malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases.
.
In addition, Junshi Bio has a number of commercial products such as Toripalimab and Atelizumab
.
The company is an unprofitable pharmaceutical company that continuously invests in the research and development of innovative drugs
.
The 2015-2021 financial report shows that the company achieved revenue of 300 million yuan, 060 million yuan, 54 million yuan, 30 million yuan, 775 million yuan, 1.
595 billion yuan, and 4.
014 billion yuan respectively; the losses in the same period were 58 million yuan, 135 million yuan, 317 million yuan, 723 million yuan, 747 million yuan, 1.
669 billion yuan, 739 million yuan
.
The industry believes that although it will be a loss in 2021, judging from the fact that Junshi Bio’s revenue has increased by 151.
71% year-on-year, the company’s profit prospects are relatively large
.
In 2021, the sales of its core product toripalimab will be about 1.
5 billion yuan
.
It is understood that from 2019 to 2021, Junshi toripalimab will have a total sales revenue of 3.
6 billion yuan, with significant sales growth
.
From 2015 to 2020, the company invested 84 million yuan, 43 million yuan, 74 million yuan, 132 million yuan, 217 million yuan, and 440 million yuan in research and development.
In addition, before 2021 In the third quarter, the company's R&D investment reached 428 million yuan, with a total of about 1.
418 billion yuan
.
However, the company's sales expenses also showed an upward trend during the same period
.
Public information shows that since 2015, Junshi Bio has completed multiple rounds of financing in the three capital markets of the New Third Board, A shares and Hong Kong shares
.
For example, in June 2021, Junshi Bio allotted and issued 36,549,200 new H shares at an issue price of HK$70.
18 per share, raising 2.
565 billion yuan (equivalent to 2.
134 billion yuan); in July 2020, the company completed the technological innovation The board IPO issued 87.
13 million A shares at an issue price of 55.
5 yuan per share, raising funds of about 4.
835 billion yuan; on January 4, 2019, the company over-allotted 23,836,500 H shares at an issue price of HK$19.
38 per share.
The capital is HKD 462 million (equivalent to RMB 404 million); in December 2018, the company completed the issuance of approximately 159 million H shares in Hong Kong shares at an issue price of HKD 19.
38 per share, raising funds of approximately HKD 3.
08 billion (equivalent to RMB 2.
713 billion).
100 million yuan); in February 2018, the company's sixth round of new third board additional financing was about 300 million yuan
.
Industry statistics show that if Junshi Biotech successfully completes fundraising in this A-share additional issuance, it means that the company's domestic and foreign capital market financing amount since 2015 will approach 15.
7 billion yuan.
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The development of the entire innovative drug industry is in full swing
.
However, innovative drugs have the characteristics of high threshold, high investment and high risk
.
As the capital market continues to be optimistic about the innovative drug industry and continues to increase its weight in this field, it is expected to promote the further development of the industry
.
Junshi Bio announced on the evening of March 7 that it plans to raise no more than 3.
98 billion yuan for innovative drug research and development projects, Shanghai Junshi Biotechnology headquarters and research and development base projects
.
Among them, more than 90% of the funds raised this time will be used for innovative drug research and development projects
.
Regarding this fundraising, Junshi Bio said that after the investment project is completed, it will further promote the company's innovative drug research and development process, enrich the pipeline of drug products under development, enhance its research and development strength, and further enhance the company's core competitiveness
.
According to the data, Junshi Bio has a rich product pipeline and currently has a rich R&D pipeline consisting of more than 45 products under development, covering five therapeutic areas of malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases.
.
In addition, Junshi Bio has a number of commercial products such as Toripalimab and Atelizumab
.
The company is an unprofitable pharmaceutical company that continuously invests in the research and development of innovative drugs
.
The 2015-2021 financial report shows that the company achieved revenue of 300 million yuan, 060 million yuan, 54 million yuan, 30 million yuan, 775 million yuan, 1.
595 billion yuan, and 4.
014 billion yuan respectively; the losses in the same period were 58 million yuan, 135 million yuan, 317 million yuan, 723 million yuan, 747 million yuan, 1.
669 billion yuan, 739 million yuan
.
The industry believes that although it will be a loss in 2021, judging from the fact that Junshi Bio’s revenue has increased by 151.
71% year-on-year, the company’s profit prospects are relatively large
.
In 2021, the sales of its core product toripalimab will be about 1.
5 billion yuan
.
It is understood that from 2019 to 2021, Junshi toripalimab will have a total sales revenue of 3.
6 billion yuan, with significant sales growth
.
From 2015 to 2020, the company invested 84 million yuan, 43 million yuan, 74 million yuan, 132 million yuan, 217 million yuan, and 440 million yuan in research and development.
In addition, before 2021 In the third quarter, the company's R&D investment reached 428 million yuan, with a total of about 1.
418 billion yuan
.
However, the company's sales expenses also showed an upward trend during the same period
.
Public information shows that since 2015, Junshi Bio has completed multiple rounds of financing in the three capital markets of the New Third Board, A shares and Hong Kong shares
.
For example, in June 2021, Junshi Bio allotted and issued 36,549,200 new H shares at an issue price of HK$70.
18 per share, raising 2.
565 billion yuan (equivalent to 2.
134 billion yuan); in July 2020, the company completed the technological innovation The board IPO issued 87.
13 million A shares at an issue price of 55.
5 yuan per share, raising funds of about 4.
835 billion yuan; on January 4, 2019, the company over-allotted 23,836,500 H shares at an issue price of HK$19.
38 per share.
The capital is HKD 462 million (equivalent to RMB 404 million); in December 2018, the company completed the issuance of approximately 159 million H shares in Hong Kong shares at an issue price of HKD 19.
38 per share, raising funds of approximately HKD 3.
08 billion (equivalent to RMB 2.
713 billion).
100 million yuan); in February 2018, the company's sixth round of new third board additional financing was about 300 million yuan
.
Industry statistics show that if Junshi Biotech successfully completes fundraising in this A-share additional issuance, it means that the company's domestic and foreign capital market financing amount since 2015 will approach 15.
7 billion yuan.
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
